In the BioHarmony Drug Report Database

"Preview" Icon

Dalfampridine

Ampyra, Fampyra (dalfampridine) is a small molecule pharmaceutical. Dalfampridine was first approved as Ampyra on 2010-01-22. It is used to treat multiple sclerosis and neurologic gait disorders in the USA. It has been approved in Europe to treat multiple sclerosis. It is known to target inward rectifier potassium channel 13, transient receptor potential cation channel subfamily V member 2, potassium voltage-gated channel subfamily A member 10, potassium voltage-gated channel subfamily C member 1, potassium voltage-gated channel subfamily B member 2, potassium voltage-gated channel subfamily D member 2, potassium voltage-gated channel subfamily A member 5, potassium voltage-gated channel subfamily D member 3, potassium voltage-gated channel subfamily A member 7, and potassium voltage-gated channel subfamily D member 1.

 

Trade Name

 

Fampyra
 

Common Name

 

dalfampridine
 

ChEMBL ID

 

CHEMBL284348
 

Indication

 

multiple sclerosis, neurologic gait disorders
 

Drug Class

 

Image (chem structure or protein)

Dalfampridine structure rendering